期刊文献+

骨肉瘤化疗耐药机制及逆转治疗的研究进展

Research progress of drug resistance mechanism on osteosarcoma chemotherapy and reverse treatment
下载PDF
导出
摘要 骨肉瘤是常见的骨源性恶性肿瘤,化疗是其重要的治疗手段,但肿瘤耐药性的存在,成为骨肉瘤复发和治疗失败的重要原因。明确其耐药机制,有效预防或逆转骨肉瘤耐药是目前临床亟待解决的问题。本文将对骨肉瘤耐药机制及其逆转策略的研究进展作一综述。 Osteosarcoma is a sort of malignant commonly-seen osteogenic sarcomas,a better treatment for it is chemother apy.However,tumor drug resistance is a key factor causing recurrence of osteosarcoma and treatment failure.Therefore,clearly understand its drug resistance mechanism and further effectively prevent or reverse osteosarcoma's drug resistance are urgent problems needed to be solved in current clinic.The article is going to review on drug resistance mechanism of osteosarcoma and strategy for its reversal.
出处 《中国医药导报》 CAS 2012年第32期23-25,共3页 China Medical Herald
基金 国家自然科学基金(青年项目)(项目名称:片仔癀对骨肉瘤多药耐药性影响的实验研究 批准号:30901916)
关键词 骨肉瘤 耐药机制 逆转 Osteosarcoma Drug resistance mechanism Reverse
  • 相关文献

参考文献34

  • 1Schwartz CL,Gorlick R,Teot L,et al. Children's Oncology Group. Mul- tiple drug resistance in osteogenie sarcoma:INTO133 from the Chil- dren's Oncology Group [J]. J Clin Oncol,2007,25 (15 ):2057-2062.
  • 2Chou AJ,Gorliek R Chemotherapy resistance in osteosarcoma:current chal- lenges and future directions [J]. Expert Rev Anticancer Ther,2006,6:1075- 1085.
  • 3Dean M,Fojo T,Bate S. Tumour stem cell and drug resistance [J]. Nat Rev Cancer, 2005,5 : 275-284.
  • 4Lourda M,Trougakos IP,Gonos ES. Development of resistance to chemother- apeutic drugs in human osteosarcoma cell lines largely depends on up- regulation of clusterin/Apolipoprotein J [J]. Int J Cancer,2007,120 (3) : 611-622.
  • 5Takara K,Sakaeda T,Okumura K. An update on overcoming MDR- lmediated multidrug resistance in cancer chemotherapy [J]. Curr Pharm Des, 2006,12(3) :273-286.
  • 6黄纲,李佛保,韩士英,沈靖南,王晋.骨肉瘤组织中多药耐药基因mdr-1mRNA和p-糖蛋白的表达及其与临床病理特点关系的研究[J].中华骨科杂志,2000,20(1):25-29. 被引量:11
  • 7Celia M,Freitas G,Heidi VP,et al. Mutidrug resistance mediated by ABC transporters in osteosarcoma cell lines:mRNA ananlysis and functional radiotracer studies [J]. Nuclear Medicine and Biology, 2006,33 : 831-840.
  • 8Michiro S,Arun KL,Keinosuke R,et al. Inhibition of ABCBI (MDRI) expression by an siRNA nanopartieulate delivery system to overcome drug resistance in osteosarcoma [J]. P Los 0ne,2010,5(5):10764.
  • 9Adams JM,Cory S. The Bel-2 apoptotic switch in cancer evelopment and therapy [J]. Oneogene, 2007,26 (9) : 1324-1337.
  • 10吴小三,张春林,赵曜,高田田,孙佼,曾炳芳.应用Cyclin D1和bcl-2为靶标的siRNA慢病毒载体构建和鉴定[J].中国组织工程研究与临床康复,2010,14(20):3709-3713. 被引量:1

二级参考文献93

共引文献144

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部